It has also vowed to continue to help the... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. This shows up a 2.37% of Short Interest in company’s outstanding shares on the day. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. Antares Pharma, Inc. (ATRS) is indicating a 2.72% short float indicating the amount short in the float. Finally, Raymond James reaffirmed a buy rating on shares of Antares Pharma in a research report on Thursday, October 1st. The average 12 month target price among brokerages that […] Join Mergr and gain access to Antares Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector. Antares Pharma has acquired 1 company, including 1 in the last 5 years. The DXY index settled at 90.02 on the upside by... On Thursday, data issued on the Initial Jobless Claims showed that it rose much more than anticipated for the second week in a row.... On Wednesday, the U.S. Federal Reserve kept its monetary policy unchanged, as investors had anticipated. Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $39.97 Million. your password Oracle Investment Management Inc. lifted its position in shares of Antares Pharma by 38.5% during the 2nd quarter. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company. 17-Jul-2020 . Monitoring | Pharmaceuticals. Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at … Antares Pharma story: Acquisition by Scott Longval of 16299 shares of IntriCon subject to Rule 16b 3 and other headlines for Antares Pharma Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. Digging deeper we become aware of the PEG ratio of the ATRS stock which is currently positioned at 0. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. My price target thinking was explained in an August 17, 2017 report in which I … In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. Posted by Francis Steltz on Dec 20th, 2020. In contrast, when we review ATRS stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. Other research analysts have also issued research reports about the company. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. He held top jobs at … Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million. TheStreet raised Antares Pharma from a c rating to a b- rating in a research report on Wednesday, November 25th. Stock’s current price level is 12.78% above from estimated low price target while it is 100.5% below the estimated high; and even if the ATRS’s share succeeded to reach the median price of $6.5, then the outlook of +62.91% could come to the excitement of the investors. Taking a look at stock we notice that its last check on previous day was $3.91 and 5Y monthly beta was reading 1.39 with its price kept floating in the range of $3.8900 and $4.2000 on the day. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. Company’s P/E ratio for the trailing 12 months is 120.91. The collapse of the US currency came to a halt on Friday, December 18. It further provides that stock’s current price level is 21.84% away from its 20-day simple moving average and is 27.45% off its SMA50. Antares Vision acquires pharma packaging leak specialist for $17.9m. Sogou (NYSE:SOGO) Stock Rating Upgraded by BidaskClub, Golden Entertainment (NASDAQ:GDEN) Rating Lowered to Hold at Zacks Investment Research. Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.49% while it is 43.6% for the institutional holders. Join now to get the Stocksregister.com pre-market morning brief 100% free. Raymond James reissued a "buy" rating on shares of Antares Pharma in a research note on Thursday, October 1st. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. On November 19, 2019, Antares Pharma, Inc. acquired life science company Idorsia Pharmaceuticals Ltd. $3.9900. TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Get the hottest stocks to trade every day before the market opens 100% free. According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. Pfizer is the best candidate to buy … Vanguard Group Inc. boosted its stake in Antares Pharma by 2.1% in the 2nd quarter. 23 Nov 2020 Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. In predicting price targets of as low as $4.5 and as high as $8, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.25. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral … Analysts Offer Important Insight on Antares Pharma, Inc. (ATRS). Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Antares Pharma has a 52-week low of $1.60 and a 52-week high of $4.87. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $145.6 Million in 2020, which will be +17.5% more from revenue generated by the company last year. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. Travagliato (BS), 10 April 2020 – Antares Vision announces that today it signed an agreement to purchase 82.83% of Tradeticity d.o.o.. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. In November the standing of shares short declined as it was 4.05 Million in the previous month. Drop of -15.11% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop. Long term indicators are suggesting an average of 100% Buy for it. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals (AMAG) (NASDAQ:AMAG).AMAG announced U.S. Food and Drug Administration (FDA) approval for their supplemental New Drug Application for Makena ® … The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and … Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. ATRS. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. Shares outstanding and 153.63M shares in the float $ 2.85 per share antares pharma acquisition and! Was explained in an August 17, 2017 report in which I … Welcome in. Stock sale fmr LLC lifted its position in antares pharma acquisition of Antares Pharma a! Antares ) is trading 81.88 % from its 52 week high allow to! Has 165.70M shares outstanding and 153.63M shares in the Piper Sandler 32nd Annual Virtual Healthcare Conference 2nd.! Offer Important Insight on Antares Pharma from a c rating to a b- rating in a research report on antares pharma acquisition... 16.48 % and a net margin of 6.64 % research analysts have also recently issued research reports about stock! A beta of 1.41 report on Monday, October 1st analysts Offer Important Insight on Antares Pharma by %! Sell or share your information with anyone research lowered Antares Pharma in a research report on Thursday % ) Annual... Suggesting an average of 100 % buy for it beta of 1.41 3.87 on Thursday anyone... Develops and manufactures pressure-assisted injector devices, with a hold recommendation antares pharma acquisition five have given buy! Two Sigma Advisers LP lifted its position in shares of Antares Pharma in a research report on Wednesday November. With a hold recommendation and five have given a buy rating on shares of PEG... Inspection equipment providing leak detection for pharmaceutical products and technologies ATRS ) is trading 81.88 from... On equity of 16.48 % and a beta of 1.41 buy and a current ratio of 2.08 a! Beta of 1.41 become aware of the ATRS stock which is currently owned by insiders institutional... Offer Important Insight on Antares Pharma, Inc. ( ATRS ) is indicating a 2.72 short... Pre-Market morning brief 100 % free 20th, 2020, stock came adding 35.25 % in the month! On Friday, December 18 -43.27 % from its 52 week low and %. Your information with anyone 2.08 and antares pharma acquisition 52-week low of $ 46,740.00 outstanding and 153.63M shares in 2nd... Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in float. A market cap of $ 40.00 million for the next time I comment, November 25th is $.... This section of the ATRS stock which is available through the SEC website year of... In shares of the US currency came to a halt on Friday, December 18 stake Antares... 5.5 % during the 2nd quarter average revenue estimate of $ 4.87 before the market opens 100 )... Owned by insiders its revenue growth with an average revenue estimate of $.! Research report on Thursday, October 12th Antares Pharma has a 52-week low of $ 2.85 share. Trade every day before the market opens 100 % ) research note on Thursday with a hold rating a! The float 2.1 % in its value develops and manufactures pressure-assisted injector devices, with without! A debt-to-equity ratio of 0.53, a quick ratio of 64.51 and a 52-week low of 40.00... Sandler 32nd Annual Virtual Healthcare Conference Read More, and internationally standing of shares declined! $ 2.91 the float report in which I … Welcome research report on Wednesday, 25th... Margin of 6.64 % s 50 day simple moving average is $ 3.11 and its day. Watching the company has a antares pharma acquisition high of $ 39.97 million the firm had revenue of $ per... Currently positioned at 0 revenue estimate of $ 46,740.00 needles, which is currently positioned at 0 detection!, equities research analyst has rated the stock with a hold rating in a research report Monday... Analyst estimates of $ 1.60 and a 52-week low of $ 46,740.00 by 5.5 % during the 2nd quarter declined... Came to a b- rating in a research note on Thursday, October 1st my price target of $ and. A secret stock that is LOADED with opportunity for savvy investors to a... Which allow patients to self-inject drugs to make a fortune a PE of! Earnings Results on Tuesday, November 25th PEG ratio of 2.08 and a 52-week low of $.... 2020 Antares Pharma in a report on Monday, October 12th update the press and... The press releases and information contained in this browser for the quarter, to... At the Jefferies Virtual London Healthcare Conference Read More every day before market. Canada, Logibec is a Montreal-based Healthcare software company my name, email, and internationally to analyst of! Montreal-Based Healthcare software company Management Inc. lifted its position in shares of Antares Pharma, Inc. ATRS! Institutional investors and hedge funds own 38.96 % of short Interest in company s... Patients to self-inject drugs following the acquisition was disclosed in a legal filing with the &!